How many email patterns does Spexis AG use?

Spexis AG uses 4 known email patterns.

What domain does Spexis AG use for work emails?

Spexis AG uses polyphor.com for work email addresses.

Most Common Email Formats at Spexis AG

Spexis AG's most common email format is First.Last@polyphor.com (ex. John.Doe@polyphor.com), used for 90% of polyphor.com addresses. Spexis AG uses 4 email patterns.

@polyphor.com

4 patterns

Format	Example	Share of polyphor.com
First.Last@polyphor.comMost common	John.Doe@polyphor.com	90%
FirstLast@polyphor.com	JohnDoe@polyphor.com	6%
First.MiddleLast@polyphor.com	John.MichaelDoe@polyphor.com	3%
Last.First@polyphor.com	Doe.John@polyphor.com	1%

Frequently Asked Questions

What does Spexis AG do?

Spexis AG was founded in 1996 and operates in the Pharmaceutical Manufacturing industry, alongside similar companies like Coastal, Zenni Optical and Eyeconic. You can visit spexisbio.com or contact Spexis AG's headquarters by phone at

+41-61-567-1****

. Explore Spexis AG's company overview page for more information.

What is Spexis AG's email address format?

Spexis AG's email format typically follows the pattern of First.Last@polyphor.com; this email format is used 90% of the time. Other contacts within LeadIQ's database had email formats such as FirstLast@polyphor.com and First.MiddleLast@polyphor.com. Looking for more contact data? Unlock accurate emails and phone numbers from millions of profiles verified in real-time.

How many employees does Spexis AG have currently?

Spexis AG has approximately 16 employees as of July 2026. Key team members to contact include Head Of Bioanalytics: M. S., Head It: T. S. and Global Head Of Hr & Operations (excom Member And Board Advisor): M. F. For more team information and contact data, explore Spexis AG's employee directory with LeadIQ.

Spexis AG Email Format

Q: What is Spexis AG's email address format?

Spexis AG's email format typically follows the pattern of ${fn}.${ln}. Other email formats include ${fn}${ln} and ${fn}.${mn}${ln}.

Pharmaceutical ManufacturingBasel-Landschaft, Switzerland11-50 Employees

Spexis AG is a publicly listed Swiss clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and oncology, established in 2021 through a reverse merger of EnBiotix, Inc. and Polyphor AG and based in Allschwil in the Basel-Landschaft region. Its lead candidate, ColiFin®, is an inhaled formulation of colistimethate sodium licensed from PARI Pharma GmbH for ex-European rights and is approved and marketed in Europe as frontline therapy for cystic fibrosis. 
 
 In the United States, ColiFin carries Orphan Drug and QIDP designations, providing twelve years of potential market exclusivity from NDA approval, and the FDA issued a Study May Proceed letter for a single Phase 3 trial intended to support an NDA, a design endorsed by the Cystic Fibrosis Foundation Therapeutic Development Network. In January 2024, Spexis entered into an asset purchase agreement with Basilea Pharmaceutica Ltd, reflecting ongoing strategic corporate development.

Most Common Email Formats at Spexis AG

@polyphor.com

Need a specific person's email?

Frequently Asked Questions

What does Spexis AG do?

What is Spexis AG's email address format?

How many employees does Spexis AG have currently?

Spexis AG Email Format

Ready to create more pipeline?

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Most Common Email Formats at Spexis AG

@polyphor.com

Need a specific person's email?

Frequently Asked Questions

What does Spexis AG do?

What is Spexis AG's email address format?

How many employees does Spexis AG have currently?

Spexis AG Email Format

Ready to create more pipeline?

Everything for prospecting,in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Everything for prospecting,
in one platform.